Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doravirine

FDA-approved product (tablet, oral), marketed as Pifeltro.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Doravirine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Doravirine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doravirine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil

    NCT04903847 · start 2021-02-02

    Registered record
    Registry ID
    NCT04903847
    Conditions
    Hiv; HIV Infections; HIV Lipodystrophy; Osteoporosis; Renal Insufficiency; Weight Gain; Obesity
    Interventions
    Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]; Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-02-02
    Completion
    2023-02-02
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv; HIV Infections; HIV Lipodystrophy; Osteoporosis +3 more
    InterventionDolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]; Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
    PhasePhase 4
    Registry statusUnknown

  • Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

    NCT04295772 · start 2020-11-26

    Registered record
    Registry ID
    NCT04295772
    Conditions
    HIV-1 Infection
    Interventions
    DOR/ISL
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-11-26
    Completion
    2023-01-25
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionDOR/ISL
    PhasePhase 2
    Registry statusCompleted

  • Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance

    NCT04495348 · start 2020-10-22

    Registered record
    Registry ID
    NCT04495348
    Conditions
    HIV-1-infection; Weight Gain
    Interventions
    Doravirine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-10-22
    Completion
    2023-06-05
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection; Weight Gain
    InterventionDoravirine
    PhaseNot recorded
    Registry statusCompleted

  • HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label

    NCT04513626 · start 2020-09-15

    Registered record
    Registry ID
    NCT04513626
    Conditions
    HIV Infections
    Interventions
    DORAVIRINE 100 MG [Pifeltro]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-09-15
    Completion
    2025-10-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDORAVIRINE 100 MG [Pifeltro]
    PhasePhase 2
    Registry statusRecruiting

  • Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

    NCT04233372 · start 2020-08-27

    Registered record
    Registry ID
    NCT04233372
    Conditions
    Hiv
    Interventions
    Delstrigo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-08-27
    Completion
    2022-07-28
    Enrolment
    399

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv
    InterventionDelstrigo
    PhasePhase 4
    Registry statusCompleted

  • HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

    NCT04334551 · start 2020-06-23

    Registered record
    Registry ID
    NCT04334551
    Conditions
    HIV Infections
    Interventions
    Doravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-06-23
    Completion
    2022-10-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDoravirine
    PhasePhase 4
    Registry statusUnknown

  • Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals

    NCT04079452 · start 2020-02-18

    Registered record
    Registry ID
    NCT04079452
    Conditions
    HIV-1-infection
    Interventions
    Doravirine; Descovy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-02-18
    Completion
    2020-08-31
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDoravirine; Descovy
    PhasePhase 3
    Registry statusCompleted

  • Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals

    NCT04097925 · start 2020-02-18

    Registered record
    Registry ID
    NCT04097925
    Conditions
    HIV-1-infection
    Interventions
    Doravirine; Descovy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-02-18
    Completion
    2020-08-24
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDoravirine; Descovy
    PhasePhase 2
    Registry statusCompleted

  • Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

    NCT04538040 · start 2019-12-19

    Registered record
    Registry ID
    NCT04538040
    Conditions
    HIV-1-infection
    Interventions
    Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-12-19
    Completion
    2021-11-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionBictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers

    NCT03894124 · start 2019-06-12

    Registered record
    Registry ID
    NCT03894124
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Doravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-06-12
    Completion
    2019-08-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionDoravirine
    PhasePhase 1
    Registry statusCompleted

  • Doravirine, Rifapentine and Isoniazid Interaction

    NCT03886701 · start 2019-04-22

    Registered record
    Registry ID
    NCT03886701
    Conditions
    Latent Tuberculosis; Human Immunodeficiency Virus; Rifamycins Causing Adverse Effects in Therapeutic Use; Drug Interaction Potentiation
    Interventions
    Doravirine (DOR); Rifapentine (RPT); Isoniazid (INH)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-22
    Completion
    2019-05-20
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis; Human Immunodeficiency Virus; Rifamycins Causing Adverse Effects in Therapeutic Use; Drug Interaction Potentiation
    InterventionDoravirine (DOR); Rifapentine (RPT); Isoniazid (INH)
    PhasePhase 1
    Registry statusCompleted

  • Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

    NCT03332095 · start 2018-07-02

    Registered record
    Registry ID
    NCT03332095
    Conditions
    HIV Infections
    Interventions
    Doravirine (DOR); Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF); Antiretroviral (ARV) medications
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-07-02
    Completion
    2022-05-25
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDoravirine (DOR); Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF); Antiretroviral (ARV) medications
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

    NCT03272347 · start 2017-11-27

    Registered record
    Registry ID
    NCT03272347
    Conditions
    HIV-1 Infection
    Interventions
    Islatravir; Placebo to Islatravir; Doravirine; Placebo to Doravirine; Lamivudine; Placebo to Lamivudine; Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate; Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate; Doravirine/Islatravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-11-27
    Completion
    2022-03-09
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionIslatravir; Placebo to Islatravir; Doravirine; Placebo to Doravirine +5 more
    PhasePhase 2
    Registry statusCompleted

  • Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

    NCT02652260 · start 2016-03-04

    Registered record
    Registry ID
    NCT02652260
    Conditions
    HIV-1; Central Nervous System
    Interventions
    Doravirine, Tenofovir, Lamivudine - Blinded; Doravirine, Tenofovir, Lamivudine - Open-Label; ATRIPLA^TM; Placebo to ATRIPLA™; Placebo to Doravirine, Tenofovir, Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-03-04
    Completion
    2024-02-07
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1; Central Nervous System
    InterventionDoravirine, Tenofovir, Lamivudine - Blinded; Doravirine, Tenofovir, Lamivudine - Open-Label; ATRIPLA^TM; Placebo to ATRIPLA™ +1 more
    PhasePhase 2
    Registry statusCompleted

  • Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)

    NCT02715700 · start 2015-09-28

    Registered record
    Registry ID
    NCT02715700
    Conditions
    Human Immunodeficiency Virus (HIV) Infection
    Interventions
    Methadone; Doravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-09-28
    Completion
    2016-08-15
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV) Infection
    InterventionMethadone; Doravirine
    PhasePhase 1
    Registry statusCompleted